AU2014286123B2 - Mammalian milk osteopontin for enhancing immune responsiveness - Google Patents

Mammalian milk osteopontin for enhancing immune responsiveness Download PDF

Info

Publication number
AU2014286123B2
AU2014286123B2 AU2014286123A AU2014286123A AU2014286123B2 AU 2014286123 B2 AU2014286123 B2 AU 2014286123B2 AU 2014286123 A AU2014286123 A AU 2014286123A AU 2014286123 A AU2014286123 A AU 2014286123A AU 2014286123 B2 AU2014286123 B2 AU 2014286123B2
Authority
AU
Australia
Prior art keywords
osteopontin
opn
mammal
vaccine
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014286123A
Other languages
English (en)
Other versions
AU2014286123A1 (en
Inventor
Sarah S. Comstock
Sharon DONOVAN
Anne Staudt Kvistgaard
Marcia H. Monaco SIEGEL
Peter Langborg WEJSE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arla Foods AMBA
Original Assignee
Arla Foods AMBA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arla Foods AMBA filed Critical Arla Foods AMBA
Publication of AU2014286123A1 publication Critical patent/AU2014286123A1/en
Application granted granted Critical
Publication of AU2014286123B2 publication Critical patent/AU2014286123B2/en
Assigned to ARLA FOODS AMBA reassignment ARLA FOODS AMBA Amend patent request/document other than specification (104) Assignors: ARLA FOODS AMBA
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dispersion Chemistry (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AU2014286123A 2013-07-05 2014-07-04 Mammalian milk osteopontin for enhancing immune responsiveness Active AU2014286123B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361843185P 2013-07-05 2013-07-05
US61/843,185 2013-07-05
EP13175267 2013-07-05
EP13175267.7 2013-07-05
PCT/EP2014/064339 WO2015001092A1 (en) 2013-07-05 2014-07-04 Mammalian milk osteopontin for enhancing immune responsiveness

Publications (2)

Publication Number Publication Date
AU2014286123A1 AU2014286123A1 (en) 2016-01-21
AU2014286123B2 true AU2014286123B2 (en) 2019-02-28

Family

ID=48740972

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014286123A Active AU2014286123B2 (en) 2013-07-05 2014-07-04 Mammalian milk osteopontin for enhancing immune responsiveness

Country Status (18)

Country Link
US (3) US9956283B2 (enExample)
EP (1) EP3016673B1 (enExample)
JP (1) JP6509833B2 (enExample)
KR (1) KR102307002B1 (enExample)
CN (1) CN105407910B (enExample)
AU (1) AU2014286123B2 (enExample)
BR (1) BR112016000067B1 (enExample)
CA (1) CA2916821C (enExample)
CL (1) CL2015003803A1 (enExample)
DK (1) DK3016673T3 (enExample)
EA (1) EA034654B1 (enExample)
ES (1) ES2656474T3 (enExample)
MX (1) MX369925B (enExample)
NZ (1) NZ715430A (enExample)
PH (1) PH12015502844B1 (enExample)
PL (1) PL3016673T3 (enExample)
PT (1) PT3016673T (enExample)
WO (1) WO2015001092A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102967831B1 (ko) * 2018-04-25 2026-05-20 헬쓰 앤드 해피니스 (에이치＆에이치) 홍콩 리미티드 의약으로 사용하기 위한 오스테오폰틴 및 2'-푸코실락토오스의 조합물
US10933097B1 (en) 2020-03-05 2021-03-02 King Saud University Method of treating a bacterial infection using colostrum
CN113424962A (zh) * 2020-09-21 2021-09-24 黑龙江飞鹤乳业有限公司 提高免疫力的营养组分、含有其的食品或保健品及其用途
EP4326758A4 (en) * 2021-04-20 2025-03-19 University of Cincinnati A vaccine adjuvant for infectious diseases
CN113475720B (zh) * 2021-06-15 2023-07-25 合生元（广州）健康产品有限公司 骨桥蛋白在增加肠道菌群多样性和增加肠道短链脂肪酸含量中的应用
EP4472656A1 (en) * 2022-01-31 2024-12-11 Société des Produits Nestlé S.A. Compositions comprising osteopontin (opn)
CN117337994A (zh) * 2023-10-11 2024-01-05 黑龙江飞鹤乳业有限公司 功能性组合物及该组合物的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056405A1 (en) * 1997-06-10 1998-12-17 Whitehead Institute For Biomedical Research A method of modulating immune response with osteopontin
WO2000063241A2 (en) * 1999-04-15 2000-10-26 Children's Medical Center Corporation Methods and compositions for modulating an immune response
US20050287247A1 (en) * 2003-09-18 2005-12-29 Sorensen Esben S Infant formula

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2293492A1 (en) * 1997-06-11 1998-12-17 Martin Berry Cns neuroregenerative compositions and methods of use
US7259243B2 (en) 2000-01-07 2007-08-21 Arla Foods Amba Process for isolation of osteopontin from milk
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
AU2003239589A1 (en) * 2002-05-24 2003-12-12 Schering-Plough Ltd. Eta-1 gene and methods for use
EP1667537B1 (en) * 2003-09-18 2013-11-06 Arla Foods Amba Infant formula
KR20090123115A (ko) 2008-05-27 2009-12-02 한국생명공학연구원 오스테오폰틴을 유효성분으로 함유하는 자연살해세포분화용 조성물 및 이를 이용한 분화 방법
AU2012222312B2 (en) * 2011-03-03 2017-06-08 Arla Foods Amba Method for isolating osteopontin using feeds containing cmp or casein species
US20150344534A1 (en) * 2011-12-07 2015-12-03 Arla Foods Amba Osteopontin variants for use in suppression or prevention of tumor growth and compositions containing such osteopontin variants

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056405A1 (en) * 1997-06-10 1998-12-17 Whitehead Institute For Biomedical Research A method of modulating immune response with osteopontin
WO2000063241A2 (en) * 1999-04-15 2000-10-26 Children's Medical Center Corporation Methods and compositions for modulating an immune response
US20050287247A1 (en) * 2003-09-18 2005-12-29 Sorensen Esben S Infant formula

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KHAJOEE V ET AL, "Novel roles of osteopontin and CXC chemokine ligand 7 in the defence against mycobacterial infection", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2006, vol. 143, no. 2, ISSN 0009-9104, pages 260 - 268 *

Also Published As

Publication number Publication date
CL2015003803A1 (es) 2016-08-05
US10772955B2 (en) 2020-09-15
CN105407910A (zh) 2016-03-16
MX369925B (es) 2019-11-25
NZ715430A (en) 2022-01-28
CA2916821C (en) 2023-10-03
BR112016000067A2 (enExample) 2017-09-05
EA034654B1 (ru) 2020-03-03
EP3016673A1 (en) 2016-05-11
USRE50281E1 (en) 2025-01-28
KR102307002B1 (ko) 2021-10-05
EA201690057A1 (ru) 2016-07-29
US20160136268A1 (en) 2016-05-19
DK3016673T3 (da) 2018-01-29
CA2916821A1 (en) 2015-01-08
MX2016000107A (es) 2016-06-07
CN105407910B (zh) 2019-12-03
KR20160030960A (ko) 2016-03-21
ES2656474T3 (es) 2018-02-27
BR112016000067B1 (pt) 2022-08-30
AU2014286123A1 (en) 2016-01-21
PT3016673T (pt) 2018-01-30
JP2016529217A (ja) 2016-09-23
JP6509833B2 (ja) 2019-05-08
PL3016673T3 (pl) 2018-04-30
PH12015502844A1 (en) 2016-03-28
US9956283B2 (en) 2018-05-01
WO2015001092A1 (en) 2015-01-08
PH12015502844B1 (en) 2016-03-28
US20180289798A1 (en) 2018-10-11
EP3016673B1 (en) 2017-10-25

Similar Documents

Publication Publication Date Title
USRE50281E1 (en) Mammalian milk osteopontin for enhancing immune responsiveness
Renz et al. The immunological basis of the hygiene hypothesis
Olivares et al. Oral intake of Lactobacillus fermentum CECT5716 enhances the effects of influenza vaccination
Perdigon et al. Interaction of lactic acid bacteria with the gut immune system
Wen et al. High dose and low dose Lactobacillus acidophilus exerted differential immune modulating effects on T cell immune responses induced by an oral human rotavirus vaccine in gnotobiotic pigs
Kusumo et al. Lactobacillus plantarum IS-10506 supplementation increases faecal sIgA and immune response in children younger than two years
JP4942831B2 (ja) 抗アレルギー用組成物
Wold Immune effects of probiotics
Saliganti et al. Feeding probiotic Lactobacillus rhamnosus (MTCC 5897) fermented milk to suckling mothers alleviates ovalbumin-induced allergic sensitisation in mice offspring
Saliganti et al. Consumption of probiotic Lactobacillus rhamnosus (MTCC: 5897) containing fermented milk plays a key role in development of the immune system in newborn mice during the suckling–weaning transition
US11883446B2 (en) Probiotics for use in the prevention or treatment of illness and/or symptoms associated with coronaviruses
Choi et al. Immune-enhancing effect of nanometric Lactobacillus plantarum nF1 (nLp-nF1) in a mouse model of cyclophosphamide-induced immunosuppression
US20020009429A1 (en) Pharmaceutical composition comprising a selected antigen and candida species antigen and methods
Borchers et al. The influence of yogurt/Lactobacillus on the innate and acquired immune response
WO2011099875A1 (en) Use of lactic acid bacteria to treat or prevent rhinitis
CN114340666A (zh) 环二核苷酸的新用途
WO2025057524A1 (ja) プラズマサイトイド樹状細胞活性化用組成物
EP0930316A1 (en) Oral product for the prevention and treatment of infectious gastroenteritides in calves
Sarabia-Sainz et al. Maillard neoglycans as inhibitors for in vitro adhesion of F4+ enterotoxigenic Escherichia coli to piglet intestinal cells
JP2005126365A (ja) 減感作療法用剤
JP2022169350A (ja) 免疫賦活剤
KR20240006134A (ko) 마이코박테리움 파라고르도네를 포함하는 면역 증강용 조성물
Shunk Effect of bovine lactoferrin on T lymphocyte cell phenotype and function and the response to vaccination in the neonatal piglet
Lu Effects of supplemental osteopontin on intestinal development and serum antibody responses to rotavirus vaccination in piglets
Rai Veterinary bacteriology

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: ARLA FOODS AMBA

Free format text: FORMER NAME(S): ARLA FOODS AMBA

FGA Letters patent sealed or granted (standard patent)